论文部分内容阅读
目的:探究与讨论沙美特罗替卡松吸入粉剂治疗慢性阻塞性肺疾病(COPD)缓解期的临床效果。方法:在2013年3月份-2014年1月份来我院就诊的56例患有慢性阻塞性肺疾病的患者作为本次的研究对象。以上患者均处于缓解期,来院之后给予沙美特罗替卡松吸入粉剂进行治疗。然后在详细记录患者吸入粉剂的前后各项指标和临床症状变化以及是否有不良反应发生。结果:在治疗以后,56例患者的症状都得到了改善,而且肺功能指标吸入前后有明显的差异,而且差异具有统计学意义(p<0.05)。而且患者吸入后没有发生严重不良反应。结论:用沙美特罗替卡松吸入粉剂治疗慢性阻塞性肺疾病缓解期效果非常好,值得在临床上推广使用。
Objective: To investigate and discuss the clinical effect of salmeterol and terbutifolia inhalation powder in the treatment of chronic obstructive pulmonary disease (COPD) remission. Methods: From March 2013 to January 2014, 56 patients with chronic obstructive pulmonary disease who came to our hospital were selected as the study subjects. All of the above patients were in remission and were given salmeterol and ticasone for inhalation after treatment. Then detailed records of patients inhaled powder before and after the various indicators and clinical symptoms and whether there are adverse reactions. Results: After treatment, the symptoms of 56 patients were improved, and there were significant differences before and after inhalation of pulmonary function index, and the difference was statistically significant (p <0.05). And no serious adverse reactions occurred after inhalation. Conclusion: Salmeterol and Ticarizon inhalation powder for chronic obstructive pulmonary disease in remission period is very good, and is worth popularizing in clinic.